Article
Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Apr 2004
Rini Brian I, Halabi Susan, Taylor John, Small Eric J, Schilsky Richard L
Abstract excerpt
The majority of sporadic clear cell renal cell carcinoma (RCC) is characterized by loss of heterozygosity of the von Hippel-Lindau (VHL) tumor suppressor gene and somatic inactivation of the remaining VHL allele. The resulting VHL gene silencing leads to induction of hypoxia-regulated genes including vascular endothelial growth factor (VEGF). Thus, therapeutic inhibition of VEGF holds promise for treatment of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.